These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2720892)

  • 1. Experience with intermediate-dose (110-120 mg/m2) epirubicin.
    Hickish T; Cunningham D; Haydock A; Coombes RC
    Cancer Chemother Pharmacol; 1989; 24(1):61-4. PubMed ID: 2720892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
    Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
    Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
    Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study.
    Blomqvist C; Hietanen P; Teerenhovi L; Rissanen P
    Eur J Cancer; 1995 Dec; 31A(13-14):2406-8. PubMed ID: 8652277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of epirubicin in advanced soft tissue sarcoma.
    Chevallier B; Montcuquet P; Fachini T; Nguyen Bui B; Kerbrat P; Bastit P; Vo Van ML
    Bull Cancer; 1990; 77(10):991-5. PubMed ID: 2249019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
    Köhler U; Olbricht SS; Fuechsel G; Kettner E; Richter B; Ridwelski K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-40-S17-43. PubMed ID: 9374091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with vincristine, epirubicin and cyclophosphamide in small cell lung carcinoma. Polish Lung Cancer Cooperative Group.
    Jassem J; Karnicka-Młodkowska H; Drozd-Lula M; Strug A; Pilarska-Machowicz A; Michalski A; Kowal E; Moś-Antkowiak R; Zych J
    Eur J Cancer; 1992; 28(2-3):473-6. PubMed ID: 1317199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.
    Habeshaw T; Paul J; Jones R; Stallard S; Stewart M; Kaye SB; Soukop M; Symonds RP; Reed NS; Rankin EM
    J Clin Oncol; 1991 Feb; 9(2):295-304. PubMed ID: 1988576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
    Lauria R; Ferrari E; Tramontana S; Morabito A; Perrone F; Maffeo A; Fiorentino R; Casella G; Iodice F; Ricchi P; Carlomagno C; Varriale E; De Placido G; De Placido S; Bianco AR; Pignata S
    Oncology; 1999; 56(4):267-73. PubMed ID: 10343189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.